See more : Learn CW Investment Corporation (LCW-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Exelixis, Inc. (EXEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exelixis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Navkar Corporation Limited (NAVKARCORP.NS) Income Statement Analysis – Financial Results
- Conroy Gold and Natural Resources plc (CGDNF) Income Statement Analysis – Financial Results
- 88 Energy Limited (88E.AX) Income Statement Analysis – Financial Results
- Hardwoods Distribution Inc. (HDI.TO) Income Statement Analysis – Financial Results
- PreAxia Health Care Payment Systems Inc. (PAXH) Income Statement Analysis – Financial Results
Exelixis, Inc. (EXEL)
About Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.61B | 1.43B | 987.54M | 967.78M | 853.83M | 452.48M | 191.45M | 37.17M | 25.11M | 31.34M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.47M | 98.67M | 75.96M | 52.86M | 51.54M | 44.32M | 41.01M | 24.76M | 10.50M | 2.27M |
| Cost of Revenue | 72.55M | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M | 15.07M | 6.55M | 3.90M | 2.04M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 202.00K | 820.00K | 1.09M | 779.00K | 0.00 | 0.00 | 0.00 | -18.60M | -5.70M | 0.00 |
| Gross Profit | 1.76B | 1.55B | 1.38B | 951.27M | 934.68M | 827.48M | 437.41M | 184.90M | 33.28M | 23.07M | 30.22M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.27M | 97.85M | 74.88M | 52.08M | 51.54M | 44.32M | 41.01M | 43.36M | 16.20M | 2.27M |
| Gross Profit Ratio | 96.04% | 96.41% | 96.32% | 96.33% | 96.58% | 96.91% | 96.67% | 96.58% | 89.52% | 91.86% | 96.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.82% | 99.17% | 98.57% | 98.53% | 100.00% | 100.00% | 100.00% | 175.11% | 154.29% | 100.00% |
| Research & Development | 1.04B | 891.81M | 693.72M | 547.85M | 336.96M | 182.26M | 112.17M | 95.97M | 96.35M | 189.10M | 178.76M | 128.88M | 156.84M | 210.68M | 234.70M | 257.39M | 225.38M | 185.48M | 141.14M | 137.72M | 127.62M | 112.01M | 82.70M | 48.46M | 21.70M | 12.10M |
| General & Administrative | 502.71M | 418.26M | 369.92M | 268.26M | 210.34M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 0.00 | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.00M | 41.60M | 31.80M | 25.10M | 17.90M | 14.80M | 8.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 542.71M | 459.86M | 401.72M | 293.36M | 228.24M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 38.96M | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 18.59M | 18.76M | 19.17M | 18.91M | 7.60M | 5.47M |
| Other Expenses | 0.00 | -197.00K | -184.00K | 912.00K | 680.00K | 397.00K | -3.54M | 7.47M | 0.00 | 9.64M | 2.35M | 9.17M | 10.14M | 32.74M | 0.00 | 41.46M | 82.08M | 39.94M | 28.82M | 21.68M | 19.25M | 19.42M | 26.95M | 37.76M | 13.30M | 5.47M |
| Operating Expenses | 1.59B | 1.35B | 1.10B | 841.21M | 565.21M | 388.62M | 271.53M | 212.11M | 153.66M | 239.93M | 229.72M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 86.22M | 35.00M | 17.57M |
| Cost & Expenses | 1.66B | 1.41B | 1.15B | 877.48M | 598.31M | 414.97M | 286.60M | 218.66M | 157.55M | 241.97M | 230.84M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 67.62M | 29.30M | 17.57M |
| Interest Income | 86.54M | 33.07M | 7.67M | 19.87M | 27.96M | 12.84M | 4.88M | 4.86M | 412.00K | 4.34M | 1.22M | 1.99M | 1.46M | 138.00K | 1.51M | 5.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 33.06M | 48.67M | 48.61M | 45.35M | 27.09M | 16.26M | 9.34M | 12.67M | 6.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.72M | 20.88M | 13.63M | 13.97M | 11.17M | 7.77M | 1.19M | 1.00M | 1.41M | 2.39M | 3.15M | 5.72M | 6.82M | 10.54M | 12.60M | 13.23M | 11.33M | 16.91M | 17.76M | 17.49M | 17.75M | 16.70M | 15.21M | 18.86M | 5.70M | 0.00 |
| EBITDA | 196.60M | 222.36M | 300.30M | 110.06M | 369.47M | 438.86M | 168.30M | -36.16M | -119.60M | -217.73M | -196.36M | -114.73M | 100.07M | -72.52M | -115.58M | -155.58M | -157.05M | -109.84M | -70.87M | -89.06M | -77.59M | -70.41M | -53.43M | -24.01M | -13.10M | -15.30M |
| EBITDA Ratio | 10.74% | 12.51% | 19.98% | 11.14% | 38.18% | 52.95% | 36.96% | -11.67% | -322.73% | -846.33% | -632.71% | -222.47% | 34.92% | -25.92% | -79.33% | -143.77% | -193.52% | -111.32% | -100.36% | -114.48% | -149.90% | -157.86% | -107.47% | 56.90% | -124.76% | -673.24% |
| Operating Income | 170.89M | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M | 165.91M | -28.12M | -121.42M | -224.46M | -200.73M | -122.44M | 89.54M | -91.40M | -121.91M | -179.31M | -157.05M | -126.75M | -93.99M | -135.20M | -96.26M | -87.82M | -75.31M | -42.86M | -18.80M | -15.30M |
| Operating Income Ratio | 9.34% | 12.51% | 19.98% | 11.14% | 38.18% | 51.40% | 36.67% | -14.69% | -326.65% | -893.86% | -640.54% | -258.03% | 30.91% | -49.39% | -80.33% | -152.14% | -138.40% | -128.46% | -123.74% | -255.79% | -186.77% | -198.15% | -183.67% | -173.12% | -179.05% | -673.24% |
| Total Other Income/Expenses | 86.64M | 32.87M | 7.49M | 20.78M | 28.64M | 13.24M | -7.33M | -42.10M | -40.27M | -44.27M | -44.12M | -25.10M | -12.54M | -1.01M | -18.94M | 3.74M | 46.03M | 25.26M | -819.00K | -2.04M | 1.14M | 3.29M | -9.36M | -38.09M | 0.00 | -370.00K |
| Income Before Tax | 257.52M | 234.35M | 294.15M | 130.84M | 398.11M | 452.09M | 158.58M | -70.22M | -169.68M | -268.72M | -244.86M | -147.54M | 76.99M | -92.40M | -140.84M | -162.85M | -86.38M | -101.49M | -94.81M | -137.25M | -95.12M | -84.53M | -84.68M | -80.96M | 0.00 | -15.67M |
| Income Before Tax Ratio | 14.07% | 14.55% | 20.50% | 13.25% | 41.14% | 52.95% | 35.05% | -36.68% | -456.48% | -1,070.14% | -781.34% | -310.93% | 26.58% | -49.93% | -92.81% | -138.18% | -76.13% | -102.86% | -124.81% | -259.65% | -184.55% | -190.73% | -206.50% | -326.98% | 0.00% | -689.52% |
| Income Tax Expense | 49.76M | 52.07M | 63.09M | 19.06M | 77.10M | -237.98M | 4.35M | 32.06M | 55.00K | -182.00K | -96.00K | 107.00K | 1.30M | -72.00K | -1.29M | -18.14M | -107.60M | 0.00 | -9.59M | 30.69M | -345.00K | 345.00K | 2.55M | 32.45M | -100.00K | 0.00 |
| Net Income | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M | -169.74M | -268.54M | -244.76M | -147.65M | 75.70M | -92.33M | -135.22M | -162.85M | -86.38M | -101.49M | -84.40M | -137.25M | -94.77M | -86.13M | -71.19M | -75.31M | -18.70M | -15.67M |
| Net Income Ratio | 11.35% | 11.31% | 16.10% | 11.32% | 33.17% | 80.82% | 34.09% | -36.68% | -456.63% | -1,069.42% | -781.03% | -311.16% | 26.14% | -49.90% | -89.10% | -138.18% | -76.13% | -102.86% | -111.11% | -259.65% | -183.88% | -194.33% | -173.60% | -304.18% | -178.10% | -689.52% |
| EPS | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.60 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| EPS Diluted | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 2.21 | 0.49 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.58 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| Weighted Avg Shares Out | 318.15M | 321.53M | 314.88M | 308.27M | 302.58M | 297.89M | 293.59M | 250.53M | 209.23M | 194.30M | 184.03M | 160.14M | 126.02M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
| Weighted Avg Shares Out (Dil) | 321.46M | 324.56M | 322.36M | 318.00M | 315.01M | 312.80M | 312.00M | 250.53M | 209.23M | 194.30M | 184.06M | 160.14M | 130.48M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
Source: https://incomestatements.info
Category: Stock Reports